Ronaldo A Ribeiro1, Carlos W S Wanderley2, Deysi V T Wong1,3, José Maurício S C Mota4, Caio A V G Leite1, Marcellus H L P Souza5, Fernando Q Cunha4, Roberto C P Lima-Júnior6. 1. Center for the Study of Cancer Treatment Toxicities, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Rua Cel Nunes de Melo, 1127, Rodolfo Teófilo, 60430-270, Fortaleza, Ceará, Brazil. 2. Center for the Study of Cancer Treatment Toxicities, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Rua Cel Nunes de Melo, 1127, Rodolfo Teófilo, 60430-270, Fortaleza, Ceará, Brazil. cwswanderley@gmail.com. 3. Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil. 4. Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. 5. Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil. 6. Center for the Study of Cancer Treatment Toxicities, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Rua Cel Nunes de Melo, 1127, Rodolfo Teófilo, 60430-270, Fortaleza, Ceará, Brazil. robertocesarpljr@gmail.com.
Abstract
PURPOSE: Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs. These side effects negatively impact therapeutic outcomes and delay subsequent cycles of chemotherapy, resulting in dose reductions and treatment discontinuation. Here, we aimed to review the experimental evidence regarding possible new targets for the management of irinotecan- and 5-FU-related intestinal mucositis. METHODS: A literature search was performed using the PubMed and MEDLINE databases. No publication time limit was set for article inclusion. RESULTS: Here, we found that clinical management of intestinal mucositis and diarrhea is somewhat ineffective at reducing symptoms, possibly due to a lack of specific targets for modulation. We observed that IL-1β contributes to the apoptosis of enterocytes in mucositis induced by 5-FU. However, 5-FU-related mucositis is far less thoroughly investigated with regard to specific molecular targets when compared to irinotecan-related disease. Several studies have proposed that a correlation exists between the intestinal microbiota, the enterohepatic recirculation of active metabolites of irinotecan, and the establishment of mucositis. However, as reviewed here, this association seems to be controversial. In addition, the pathogenesis of irinotecan-induced mucositis appears to be orchestrated by interleukin-1/Toll-like receptor family members, leading to epithelial cell apoptosis. CONCLUSIONS: IL-1β, IL-18, and IL-33 and the receptors IL-1R, IL-18R, ST2, and TLR-2 are potential therapeutic targets that can be modulated to minimize anticancer agent-associated toxicity, optimize cancer treatment dosing, and improve clinical outcomes. In this context, the pathogenesis of mucositis caused by other anticancer agents should be further investigated.
PURPOSE:Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs. These side effects negatively impact therapeutic outcomes and delay subsequent cycles of chemotherapy, resulting in dose reductions and treatment discontinuation. Here, we aimed to review the experimental evidence regarding possible new targets for the management of irinotecan- and 5-FU-related intestinal mucositis. METHODS: A literature search was performed using the PubMed and MEDLINE databases. No publication time limit was set for article inclusion. RESULTS: Here, we found that clinical management of intestinal mucositis and diarrhea is somewhat ineffective at reducing symptoms, possibly due to a lack of specific targets for modulation. We observed that IL-1β contributes to the apoptosis of enterocytes in mucositis induced by 5-FU. However, 5-FU-related mucositis is far less thoroughly investigated with regard to specific molecular targets when compared to irinotecan-related disease. Several studies have proposed that a correlation exists between the intestinal microbiota, the enterohepatic recirculation of active metabolites of irinotecan, and the establishment of mucositis. However, as reviewed here, this association seems to be controversial. In addition, the pathogenesis of irinotecan-induced mucositis appears to be orchestrated by interleukin-1/Toll-like receptor family members, leading to epithelial cell apoptosis. CONCLUSIONS: IL-1β, IL-18, and IL-33 and the receptors IL-1R, IL-18R, ST2, and TLR-2 are potential therapeutic targets that can be modulated to minimize anticancer agent-associated toxicity, optimize cancer treatment dosing, and improve clinical outcomes. In this context, the pathogenesis of mucositis caused by other anticancer agents should be further investigated.
Entities:
Keywords:
Cancer chemotherapy; Cytokines; Inflammation; Intestine; Irinotecan; Mucositis; Toll-like receptors
Authors: T Sobue; M Bertolini; A Thompson; D E Peterson; P I Diaz; A Dongari-Bagtzoglou Journal: Mol Oral Microbiol Date: 2018-02-20 Impact factor: 3.563
Authors: Andreas U Lindner; Alexa J Resler; Steven Carberry; Kasia Oficjalska; Orna Bacon; Chun Seng Lee; Abdurehman Choudhry; John P Burke; Kieran Sheahan; Mattia Cremona; Bryan T Hennessy; Deborah McNamara; Glen Doherty; Elizabeth J Ryan; Jochen H M Prehn Journal: J Mol Med (Berl) Date: 2019-12-17 Impact factor: 4.599
Authors: Andrey V Panchenko; Elena I Fedoros; Sergey E Pigarev; Mikhail A Maydin; Ekaterina A Gubareva; Maria N Yurova; Galina S Kireeva; Galina P Lanskikh; Margarita L Tyndyk; Vladimir N Anisimov Journal: Exp Ther Med Date: 2018-01-22 Impact factor: 2.447
Authors: Luana David do Carmo; Gisele de Fátima Pinheiro Rangel; Liviane Maria Alves Rabelo; Tamiris de Fátima Goebel de Souza; Roberto César Pereira Lima Júnior; Deysi Viviana Tenazoa Wong; Renata Ferreira de Carvalho Leitão; Alfredo Augusto Vasconcelos da Silva; Pedro Jorge Caldas Magalhães; Andréa Santos Costa; Dyély de Carvalho Oliveira Campos; Nylane Maria Nunes de Alencar; Hermógenes David de Oliveira Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2022-07-01 Impact factor: 3.195
Authors: A T Sougiannis; B N VanderVeen; R T Enos; K T Velazquez; J E Bader; M Carson; I Chatzistamou; M Walla; M M Pena; J L Kubinak; M Nagarkatti; J A Carson; E A Murphy Journal: Brain Behav Immun Date: 2019-02-23 Impact factor: 19.227
Authors: Alexander T Sougiannis; Brandon N VanderVeen; J Mark Davis; Daping Fan; E Angela Murphy Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-01-20 Impact factor: 4.052